ATTR-CM Market Shifts as Competition Challenges Legacy Dominance
The ATTR-CM market is changing in 2026 due to new treatments and regulatory shifts. Pfizer's tafamidis faces competition from BridgeBio's Attruby and Alnylam's Amvuttra. Regulatory scrutiny of PBMs may impact access to newer therapies, with patient advocacy groups and economists monitoring the situation. Industry analysts suggest competition could lower costs and improve outcomes, depending on PBM transparency reforms.
How this was made
The 30-second read
Why it matters
Regulatory pressure could shift market share toward newer, potentially lower‑cost therapies if formulary inclusion improves.
Market read
Regulatory changes to PBM rebate practices could reallocate market share in a niche cardiology segment.
What to watch
Potential pricing negotiations between manufacturers and PBMs could mitigate regulatory effects.
Background
The article reviews how intensified U.S. regulatory scrutiny of pharmacy benefit managers is influencing the ATTR‑CM therapeutic landscape, challenging Pfizer's tafamidis dominance and opening space for BridgeBio and Alnylam.
Ticker impact
Article discusses how PBM regulatory scrutiny may erode market share for Pfizer's tafamidis in ATTR-CM.
Downside pressure if PBM reforms limit rebates for legacy drugs.
Regulatory focus on PBMs could reduce rebate-driven advantage for high‑cost incumbents.
BridgeBio's Attruby is highlighted as a new entrant that could benefit from PBM reforms in the ATTR‑CM market.
Potential upside if formulary inclusion expands.
Regulatory changes could lower barriers for newer, lower‑cost therapies.
Alnylam's Amvutra is mentioned as another new therapy facing the same PBM regulatory environment.
Possible share lift if reimbursement improves.
Same regulatory dynamics apply to Alnylam as to BridgeBio.
Market effects
PBM reforms could reshape the rare‑cardiac‑disease drug sector, favoring newer entrants.
U.S. market most affected; global peers may follow similar regulatory trends.
Limited to markets with comparable PBM structures.
Counterpoint
PBM reforms may be delayed or softened, limiting impact on incumbent pricing power.
Key entities
- CompanyPfizer Inc.
Current market leader with tafamidis.
- CompanyBridgeBio Pharma Inc.
Developer of Attruby, a new ATTR‑CM therapy.
- CompanyAlnylam Pharmaceuticals Inc.
Developer of Amvutra, another emerging ATTR‑CM drug.
